Lineage Cell Therapeutics (LCTX) Tax Provisions (2014 - 2023)

Lineage Cell Therapeutics has reported Tax Provisions for 4 years, with the latest figure at -$1.8 million in Q1 2023.

• For the quarter ending Q1 2023, Tax Provisions changed N/A year-over-year to -$1.8 million; the trailing twelve-month figure through Dec 2023 stood at -$1.8 million (up 87.14% YoY), and the FY2025 full-year result was -$5.3 million, changed N/A from the prior year.
• Tax Provisions for Q1 2023 stood at -$1.8 million, down from -$1.0 million in the prior quarter.
• The five-year high for Tax Provisions was $4.4 million in Q1 2019, with the low at -$14.0 million in Q4 2019.
• Historically, Tax Provisions has averaged -$1.7 million across 3 years, with a median of -$6000.0 in 2019.